FOXP1在上皮性卵巢癌中的表达及其与化疗耐药和预后的关系

Expression of FOXP1 in Epithelial Ovarian Cancer and its Relationship with Chemoresistance and Prognosis

目的:探讨叉头框转录蛋白1(FOXP1)在上皮性卵巢癌(EOC)中的表达及其与患者化疗耐药和预后的关系。方法:收集经手术后病理检查证实为EOC的60例患者,所有患者术后均接受以铂类为基础的规范化静脉化疗方案,采用免疫组化法测定EOC癌组织及癌旁组织FOXP1表达情况,分析FOXP1表达与EOC临床病理参数的关系;依据化疗敏感性分组,总结FOXP1表达与EOC化疗耐药的关系;并采用Kaplan-Meier法进行生存分析,并以Cox回归分析筛选EOC预后影响因素。结果:①EOC癌组织FOXP1表达阳性率明显高于癌旁组织(73.33%vs 11.67%,P<0.05);②临床分期为Ⅲ~Ⅳ期(86.67%)、病理分化程度为中、低分化(76.67%、93.75%)、伴淋巴结转移(93.33%)的EOC患者癌组织FOXP1表达阳性率显著高于临床分期为Ⅰ~Ⅱ期(33.33%)、病理分化为高分化(42.86%)且不伴淋巴结转移(66.67%)的EOC患者(P<0.05);③耐药患者癌组织FOXP1阳性率显著高于敏感患者(100.00%vs 66.67%,P<0.05);④FOXP1阴性EOC患者累积生存时间显著高于FOXP1阳性患者(35.05月vs 29.06月,P<0.05);⑤FOXP1表达、临床分期、病理分化程度、淋巴结转移、化疗敏感程度均为EOC预后的影响因素(P<0.05)。结论:EOC癌组织FOXP1呈异常高表达,且FOXP1与EOC分化程度、临床分期、肿瘤转移密切相关,FOXP1可能为预测EOC化疗耐药及不良预后的分子标志物。

Objective:To explore the expression of forkhead box protein 1(FOXP1)in epithelial ovarian cancer(EOC)and its relationship with chemoresistance and prognosis.Methods:60 patients with EOC confirmed by pathological examination after operation were enrolled.All patients received platinum-based standardized intrave-nous chemotherapy regimen after surgery.The expression of FOXP1 in EOC tissues and adjacent tissues was measured by immunohistochemistry.The relationship between FOXP1 expression and clinical pathological param-eters of EOC was analyzed.The relationship between FOXP1 expression and EOC chemoresistance was summa-rized according to chemosensitivity grouping.Survival analysis was performed by Kaplan-Meier method.The influ-encing factors of EOC prognosis were analyzed by Cox regression analysis.Results:①The positive rate of FOXP1 expression in EOC tissues was significantly higher than that in adjacent tissues(73.33%vs 11.67%)(P<0.05).②The positive rate of FOXP1 expression in cancer tissues of EOC patients with clinical stageⅢ-Ⅳ(86.67%),moderate and low pathological differentiation(76.67%,93.75%)and lymph node metastasis(93.33%)was higher than that of patients with clinical stageⅠ-Ⅱ(33.33%),high pathological differentiation(42.86%)and without lymph node metastasis(66.67%)(P<0.05).③The FOXP1 positive rate in drug-resistant group was higher than that in sensitive group(100.00%vs 66.67%)(P<0.05).④The cumulative survival period of EOC patients with negative FOXP1 was longer than that in patients with positive FOXP1(35.05 mon vs 29.06 mon,P<0.05).⑤FOXP1 expression,clinical stages,pathological differentiation,lymph node metastasis and chemotherapy sensitivity were all influencing factors of EOC prognosis(P<0.05).Conclusions:FOXP1 is abnor-mally highly expressed in EOC tissues.FOXP1 is closely related to EOC differentiation,clinical stage and tumor metastasis.It may be a molecular marker for predicting EOC chemoresistance and poor prognosis.